{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:16:28Z","timestamp":1769170588724,"version":"3.49.0"},"reference-count":80,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Brain metastases are a common yet dismal complication of metastatic cancers, originating most commonly from nonsmall cell lung cancer, breast cancer, melanoma, and renal cell carcinoma. While the current standard of care for most patients involves radiation therapy, the associated side effects have caused clinicians and researchers to search for new treatments with hopefully fewer adverse effects. The growing field of immunotherapy, including immune checkpoint inhibitors, shows promising results in cancer patients with brain metastases and warrants further investigation.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000806","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:00:19Z","timestamp":1769112019000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Role of Immunotherapy and Targeted Agents to Treat Brain Metastases"],"prefix":"10.1097","volume":"32","author":[{"given":"Nicole","family":"Hajdari","sequence":"first","affiliation":[{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland"},{"name":"College of Medicine and Life Sciences, The University of Toledo, Toledo, OH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-5176","authenticated-orcid":false,"given":"David M.","family":"Peereboom","sequence":"additional","affiliation":[{"name":"Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"R1-20260122","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.nec.2020.06.001","article-title":"Epidemiology of brain metastases","volume":"31","author":"Sacks","year":"2020","journal-title":"Neurosurg Clin N Am"},{"key":"R2-20260122","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"R3-20260122","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1017\/cjn.2020.224","article-title":"Brain metastases: a modern multidisciplinary approach","volume":"48","author":"O\u2019Halloran","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"R4-20260122","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1001\/jamaoncol.2022.5049","article-title":"Association of long-term outcomes with stereotactic radiosurgery vs whole-brain radiotherapy for resected brain metastasis: a secondary analysis of the N107C\/CEC.3 (Alliance for Clinical Trials in Oncology\/Canadian Cancer Trials Group) Randomized Clinical Trial","volume":"8","author":"Palmer","year":"2022","journal-title":"JAMA Oncol"},{"key":"R5-20260122","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3389\/fsurg.2016.00030","article-title":"The current and future treatment of brain metastases","volume":"3","author":"Hardesty","year":"2016","journal-title":"Front Surg"},{"key":"R6-20260122","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"R7-20260122","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fonc.2018.00161","article-title":"Mechanisms and therapy for cancer metastasis to the brain","volume":"8","author":"Franchino","year":"2018","journal-title":"Front Oncol"},{"key":"R8-20260122","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41467-022-27987-5","article-title":"Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities","volume":"13","author":"Cosgrove","year":"2022","journal-title":"Nat Commun"},{"key":"R9-20260122","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/s41467-021-21789-x","article-title":"Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment","volume":"12","author":"Rubio-Perez","year":"2021","journal-title":"Nat Commun"},{"key":"R10-20260122","doi-asserted-by":"crossref","first-page":"102830","DOI":"10.1016\/j.critrevonc.2019.102830","article-title":"Combination of radiotherapy and immunotherapy for brain metastases: a systematic review and meta-analysis","volume":"144","author":"Petrelli","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"R11-20260122","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s11912-024-01593-8","article-title":"Immunotherapeutic and targeted strategies for managing brain metastases from common cancer origins: a state-of-the-art review","volume":"26","author":"Podder","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"pt 2","key":"R12-20260122","doi-asserted-by":"crossref","first-page":"113365","DOI":"10.1016\/j.intimp.2024.113365","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"R13-20260122","doi-asserted-by":"crossref","first-page":"20220559","DOI":"10.1515\/biol-2022-0559","article-title":"Comparison of immunotherapy combined with stereotactic radiotherapy and targeted therapy for patients with brain metastases: a systemic review and meta-analysis","volume":"18","author":"Su","year":"2023","journal-title":"Open Life Sci"},{"key":"R14-20260122","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"R15-20260122","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"R16-20260122","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: a Society for Neuro-Oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol"},{"key":"R17-20260122","doi-asserted-by":"crossref","first-page":"102324","DOI":"10.1016\/j.ctrv.2021.102324","article-title":"Targeting brain metastases in breast cancer","volume":"103","author":"Corti","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"R18-20260122","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3390\/cancers13010142","article-title":"The network of cytokines in brain metastases","volume":"13","author":"Fares","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R19-20260122","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41568-019-0220-y","article-title":"Brain metastasis","volume":"20","author":"Boire","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"R20-20260122","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2022.11.012","article-title":"Immunotherapy for brain metastases and primary brain tumors","volume":"179","author":"Di Giacomo","year":"2023","journal-title":"Eur J Cancer"},{"key":"R21-20260122","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2021.12.043","article-title":"Cellular architecture of human brain metastases","volume":"185","author":"Gonzalez","year":"2022","journal-title":"Cell"},{"key":"R22-20260122","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"R23-20260122","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.cell.2020.05.007","article-title":"Interrogation of the microenvironmental landscape in brain tumors reveals disease-specific alterations of immune cells","volume":"181","author":"Klemm","year":"2020","journal-title":"Cell"},{"key":"R24-20260122","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1016\/j.cell.2023.08.043","article-title":"The local microenvironment drives activation of neutrophils in human brain tumors","volume":"186","author":"Maas","year":"2023","journal-title":"Cell"},{"key":"R25-20260122","doi-asserted-by":"crossref","first-page":"1006284","DOI":"10.3389\/fonc.2022.1006284","article-title":"Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis","volume":"12","author":"Xie","year":"2022","journal-title":"Front Oncol"},{"key":"R26-20260122","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2004.00.1768","article-title":"Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases","volume":"24","author":"Suh","year":"2006","journal-title":"J Clin Oncol"},{"key":"R27-20260122","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.ccell.2024.09.012","article-title":"Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade","volume":"42","author":"Fu","year":"2024","journal-title":"Cancer Cell"},{"key":"R28-20260122","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fonc.2018.00208","article-title":"Management of brain metastases in epidermal growth factor receptor mutant non-small-cell lung cancer","volume":"8","author":"Kelly","year":"2018","journal-title":"Front Oncol"},{"key":"R29-20260122","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"Wu","year":"2018","journal-title":"J Clin Oncol"},{"key":"R30-20260122","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"R31-20260122","first-page":"100205","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"R32-20260122","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R33-20260122","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"R34-20260122","first-page":"vdad018","article-title":"Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases","volume":"5","author":"Wong","year":"2023","journal-title":"Neurooncol Adv"},{"key":"R35-20260122","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-019-0133-7","article-title":"If we build it they will come: targeting the immune response to breast cancer","volume":"5","author":"Gatti-Mays","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"R36-20260122","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"key":"R37-20260122","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/cam4.5021","article-title":"Breast cancer brain metastasis: current evidence and future directions","volume":"12","author":"Sun","year":"2023","journal-title":"Cancer Med"},{"key":"R38-20260122","doi-asserted-by":"crossref","first-page":"6707","DOI":"10.1038\/s41467-024-50558-9","article-title":"Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial","volume":"15","author":"Balinda","year":"2024","journal-title":"Nat Commun"},{"key":"R39-20260122","doi-asserted-by":"crossref","first-page":"102868","DOI":"10.1016\/j.ctrv.2024.102868","article-title":"CAR-T cell therapy for breast cancer: current status and future perspective","volume":"133","author":"Buono","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"R40-20260122","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","article-title":"Regional delivery of chimeric antigen receptor-engineered T cells effectively targets HER2(+) breast cancer metastasis to the brain","volume":"24","author":"Priceman","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"s8","key":"R41-20260122","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/cncr.35096","article-title":"Chimeric antigen receptor-based immunotherapy in breast cancer: recent progress in China","volume":"130","author":"Yu","year":"2024","journal-title":"Cancer"},{"key":"R42-20260122","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.3390\/ijms26083920","article-title":"Immunotherapy in breast cancer: beyond immune checkpoint inhibitors","volume":"26","author":"Choi","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R43-20260122","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14760584.2022.2021884","article-title":"Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence","volume":"21","author":"Abbaspour","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"R44-20260122","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R45-20260122","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14712598.2021.1922665","article-title":"Bispecific antibodies for the treatment of breast cancer","volume":"22","author":"Dillon","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"R46-20260122","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"R47-20260122","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.euf.2017.12.007","article-title":"The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort","volume":"5","author":"Sun","year":"2019","journal-title":"Eur Urol Focus"},{"key":"R48-20260122","doi-asserted-by":"crossref","first-page":"103600","DOI":"10.1016\/j.critrevonc.2022.103600","article-title":"Global management of brain metastasis from renal cell carcinoma","volume":"171","author":"Pierrard","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R49-20260122","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"R50-20260122","doi-asserted-by":"crossref","first-page":"e007240","DOI":"10.1136\/jitc-2023-007240","article-title":"Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases","volume":"11","author":"Schoenfeld","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R51-20260122","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and efficacy of nivolumab in brain metastases from renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study","volume":"37","author":"Flippot","year":"2019","journal-title":"J Clin Oncol"},{"key":"R52-20260122","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"R53-20260122","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"key":"R54-20260122","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2017.11.041","article-title":"Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma","volume":"100","author":"Chen","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R55-20260122","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"key":"R56-20260122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ccell.2025.01.008","article-title":"Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases","volume":"43","author":"Rodriguez-Baena","year":"2025","journal-title":"Cancer Cell"},{"key":"R57-20260122","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/exd.14286","article-title":"Melanoma brain metastases: biological basis and novel therapeutic strategies","volume":"31","author":"Phadke","year":"2022","journal-title":"Exp Dermatol"},{"key":"R58-20260122","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"key":"R59-20260122","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/JCO.21.02314","article-title":"Treatment for brain metastases: ASCO-SNO-ASTRO guideline","volume":"40","author":"Vogelbaum","year":"2022","journal-title":"J Clin Oncol"},{"key":"R60-20260122","doi-asserted-by":"crossref","first-page":"592796","DOI":"10.3389\/fonc.2020.592796","article-title":"Stereotactic radiosurgery with concurrent immunotherapy in melanoma brain metastases is feasible and effective","volume":"10","author":"Liermann","year":"2020","journal-title":"Front Oncol"},{"key":"R61-20260122","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.7150\/jca.93306","article-title":"\u2018Immunotherapeutic strategies for intra-cranial metastatic melanoma\u2013a meta-analysis and systematic review\u2019","volume":"15","author":"Tang","year":"2024","journal-title":"J Cancer"},{"key":"R62-20260122","doi-asserted-by":"crossref","first-page":"113287","DOI":"10.1016\/j.ejca.2023.113287","article-title":"Stereotactic radiosurgery and anti-PD-1 + CTLA-4 therapy, anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF\/MEK inhibitors, BRAF inhibitors, or conventional chemotherapy for the management of melanoma brain metastases","volume":"192","author":"Dohm","year":"2023","journal-title":"Eur J Cancer"},{"key":"R63-20260122","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"R64-20260122","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12032-017-0919-0","article-title":"Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review","volume":"34","author":"Ghidini","year":"2017","journal-title":"Med Oncol"},{"key":"R65-20260122","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/0115680096283210240209062301","article-title":"Twenty-four-month progression-free survival in HER2-amplified advanced gastric cancer with brain metastases after trastuzumab deruxtecan treatment: a case report and literature review","volume":"25","author":"Zhang","year":"2025","journal-title":"Curr Cancer Drug Targets"},{"key":"R66-20260122","doi-asserted-by":"crossref","first-page":"758681","DOI":"10.3389\/fonc.2022.758681","article-title":"Risk factors on the incidence and prognostic effects of colorectal cancer with brain metastasis: a SEER-based study","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"R67-20260122","doi-asserted-by":"crossref","first-page":"1418580","DOI":"10.3389\/fimmu.2024.1418580","article-title":"Immunotherapy revolutionizing brain metastatic cancer treatment: personalized strategies for transformative outcomes","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"R68-20260122","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.wneu.2020.02.152","article-title":"Prostate cancer brain metastases: a single-institution experience","volume":"138","author":"Bhambhvani","year":"2020","journal-title":"World Neurosurg"},{"key":"R69-20260122","doi-asserted-by":"crossref","first-page":"a006094","DOI":"10.1101\/mcs.a006094","article-title":"Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade","volume":"7","author":"Sena","year":"2021","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"R70-20260122","doi-asserted-by":"crossref","first-page":"e009063","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R71-20260122","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.clbc.2022.07.004","article-title":"Exclusion of patients with brain metastases in published phase III clinical trials for advanced breast cancer","volume":"22","author":"Sharma","year":"2022","journal-title":"Clin Breast Cancer"},{"key":"R72-20260122","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms23052847","article-title":"Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment","volume":"23","author":"Dobosz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R73-20260122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"R74-20260122","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2174\/156800912799277511","article-title":"The blood-brain barrier: its influence in the treatment of brain tumors metastases","volume":"12","author":"Fortin","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"key":"R75-20260122","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/1758834017736252","article-title":"Targeted therapy of brain metastases: latest evidence and clinical implications","volume":"9","author":"Di Lorenzo","year":"2017","journal-title":"Ther Adv Med Oncol"},{"key":"R76-20260122","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/neuonc\/now197","article-title":"Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma","volume":"19","author":"Chamberlain","year":"2017","journal-title":"Neuro Oncol"},{"key":"R77-20260122","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.2006.09.9861","article-title":"Chemotherapy delivery issues in central nervous system malignancy: a reality check","volume":"25","author":"Muldoon","year":"2007","journal-title":"J Clin Oncol"},{"key":"R78-20260122","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/onco.13575","article-title":"Emerging immunotherapies in the treatment of brain metastases","volume":"26","author":"Nieblas-Bedolla","year":"2021","journal-title":"Oncologist"},{"key":"R79-20260122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-023-01818-7","article-title":"Immunotherapy: an emerging modality to checkmate brain metastasis","volume":"22","author":"Ahmad","year":"2023","journal-title":"Mol Cancer"},{"key":"R80-20260122","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/cancers16193388","article-title":"Immune checkpoint inhibitors in the management of brain metastases from non-small cell lung cancer: a comprehensive review of current trials, guidelines and future directions","volume":"16","author":"Ranjan","year":"2024","journal-title":"Cancers (Basel)"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000806","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T20:00:27Z","timestamp":1769112027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000806","relation":{},"ISSN":["1540-336X"],"issn-type":[{"value":"1540-336X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-08-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}